Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology - PubMed (original) (raw)

Review

Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology

Jan Stenvang Jepsen et al. Oligonucleotides. 2004.

Abstract

Locked nucleic acid (LNA) is a class of nucleic acid analogs possessing very high affinity and excellent specificity toward complementary DNA and RNA, and LNA oligonucleotides have been applied as antisense molecules both in vitro and in vivo. In this review, we briefly describe the basic physiochemical properties of LNA and some of the difficulties that may be encountered when applying LNA technology. The central part of the review focuses on the use of LNA molecules in regulation of gene expression, including delivery to cells, stability, unspecific effects, toxicity, pharmacokinetics, and design of LNA oligonucleotides. The last part evaluates LNA as a diagnostic tool in genotyping.

PubMed Disclaimer

Similar articles

• LNA-antisense rivals siRNA for gene silencing.
  Jepsen JS, Wengel J. Jepsen JS, et al. Curr Opin Drug Discov Devel. 2004 Mar;7(2):188-94. Curr Opin Drug Discov Devel. 2004. PMID: 15603252 Review.
• Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development.
  Orum H, Wengel J. Orum H, et al. Curr Opin Mol Ther. 2001 Jun;3(3):239-43. Curr Opin Mol Ther. 2001. PMID: 11497347 Review.
• Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA).
  Jepsen JS, Pfundheller HM, Lykkesfeldt AE. Jepsen JS, et al. Oligonucleotides. 2004;14(2):147-56. doi: 10.1089/1545457041526281. Oligonucleotides. 2004. PMID: 15294077
• LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA.
  Vester B, Wengel J. Vester B, et al. Biochemistry. 2004 Oct 26;43(42):13233-41. doi: 10.1021/bi0485732. Biochemistry. 2004. PMID: 15491130 Review.
• Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA.
  Frieden M, Christensen SM, Mikkelsen ND, Rosenbohm C, Thrue CA, Westergaard M, Hansen HF, Ørum H, Koch T. Frieden M, et al. Nucleic Acids Res. 2003 Nov 1;31(21):6365-72. doi: 10.1093/nar/gkg820. Nucleic Acids Res. 2003. PMID: 14576324 Free PMC article.

Cited by

• Biological functions and clinical applications of exosomal long non-coding RNAs in cancer.
  Wang Y, Zhang M, Zhou F. Wang Y, et al. J Cell Mol Med. 2020 Oct;24(20):11656-11666. doi: 10.1111/jcmm.15873. Epub 2020 Sep 14. J Cell Mol Med. 2020. PMID: 32924276 Free PMC article. Review.
• Unrestricted accessibility of short oligonucleotides to RNA.
  Gamper HB Jr, Arar K, Gewirtz A, Hou YM. Gamper HB Jr, et al. RNA. 2005 Sep;11(9):1441-7. doi: 10.1261/rna.2670705. RNA. 2005. PMID: 16120834 Free PMC article.
• Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles.
  Bost JP, Barriga H, Holme MN, Gallud A, Maugeri M, Gupta D, Lehto T, Valadi H, Esbjörner EK, Stevens MM, El-Andaloussi S. Bost JP, et al. ACS Nano. 2021 Sep 28;15(9):13993-14021. doi: 10.1021/acsnano.1c05099. Epub 2021 Sep 10. ACS Nano. 2021. PMID: 34505766 Free PMC article. Review.
• Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies.
  Anwar S, Mir F, Yokota T. Anwar S, et al. Pharmaceutics. 2023 Apr 3;15(4):1130. doi: 10.3390/pharmaceutics15041130. Pharmaceutics. 2023. PMID: 37111616 Free PMC article. Review.
• MicroRNA Targets for Asthma Therapy.
  Ramelli SC, Gerthoffer WT. Ramelli SC, et al. Adv Exp Med Biol. 2021;1303:89-105. doi: 10.1007/978-3-030-63046-1_6. Adv Exp Med Biol. 2021. PMID: 33788189

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • The Lens - Patent Citations Database